This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich

What the data shows is Three years ago, Summit Therapeutics (SMMT 1

Furthermore, As is often the case in the bio industry, Summit Therapeutics owes this terrific run to clinical gress from its leading pipeline candidate

And even after the significant gains it has experienced in recent years, it might still be early enough to get on the bandwagon, given the current landscape

Moreover, Here's what investors need to know

Additionally, SMMT Total Return Level data by YCharts Taking on a giant of the industry Summit Therapeutics' leading candidate, ivonescimab, was originally developed by Akeso Biopharma, a China-based bio company

On the other hand, Moreover, Summit's licensing agreement with its partner granted the former the rights to the medicine in most regions, especially those that drugmakers target the most, the U

Nevertheless, And Europe, since they tend to be the most lucrative (noteworthy indeed)

Ivonescimab is apved in China

Nevertheless, Summit is running clinical trials for the medicine to earn commercialization rights in the U, in light of current trends

However, What makes this investigational medicine revolutionary

On the other hand, However, In a phase 3 study conducted in China, ivonescimab ved just as effective -- indeed, even more effective -- than Merck's Keytruda in reducing the risk of gression or death in patients with non-small cell lung cancer (NSCLC) and a PD-L1 tein overexpression (which is quite significant)

Image source: Getty Images

Let's put that achievement in context (an important development), amid market uncertainty

Conversely, According to Summit Therapeutics, it was the first time any medicine beat out Keytruda in a head-to-head late-stage study in NSCLC

Keytruda isn't just any cancer medicine; it is currently the world's top-selling drug

And as it so happens, NSCLC is one of its more important, given the current landscape

Not only was it one of its first indications in the U

On the other hand, A potential pipeline in a drug Here's another reason ivonescimab is so mising, The medicine is being investigated as a potential therapy across a wide range of different cancers

Some of the medicine's targets include colorectal cancer, hepatocellular carcinoma (r cancer), and more, in this volatile climate

Moreover, Summit's crown jewel is emulating Keytruda in this way as well: It could be a potential pipeline in a drug

Although NSCLC should be its most important market, the medicine could also earn a slew of label expansions regularly, leading to consistent revenue and earnings growth over a long period (which is quite significant)

Some might argue that ivonescimab's success is already baked into Summit Therapeutics' stock price

After the company's impressive run, is there any upside left

Moreover, In my view, there is, vided ivonescimab ders

There's already a substantial amount of data on the medicine's safety and efficacy from trials conducted in China (an important development)

While that cannot be used to support apval in the U. , it helps eliminate some of the risk involved in in clinical-stage bio companies whose pipeline candidates have never been apved by any regulatory authorities anywhere

Nevertheless, Summit Therapeutics is not your average, young bio that generates no revenue and consistently operates at a loss

Moreover, Even with that, there is still some risk that Summit's mising drug will eventually encounter clinical or regulatory setbacks -- something even seasoned drugmakers experience

Further, competition is heating up in the bispecific antibody (the class of drugs ivonescimab belongs to) market, with several major pharmaceutical companies, including Merck, dipping their toes in this space

Furthermore, It's essential to consider these potential challenges, but Summit Therapeutics' s remain attractive due to ivonescimab's outstanding potential

Initiating a position in the company's s today could lead to monster returns over the long run

Furthermore, Sper Junior Bakiny has no position in any of the stocks mentioned, in light of current trends

The Motley Fool has positions in and recommends Merck and Summit Therapeutics

The Motley Fool has a disclosure policy (something worth watching), in light of current trends.